Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Stanley Medical Research Institute
• Treatments: Cannabidiol; Cannabinoid Receptor Antagonists

Criteria

Inclusion Criteria:

• Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria:

• Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.